CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
DLBCL 活体供者接受 CD19/CD22 CAR-T 细胞鸡尾酒疗法后长期完全缓解及轻微副作用：一例罕见病例报告
英文原题：Long-term complete remission and minimal side effects after CD19/CD22 CAR-T cell cocktail therapy in a living donor with DLBCL: A rare case report.
查看英文原题
Long-term complete remission and minimal side effects after CD19/CD22 CAR-T cell cocktail therapy in a living donor with DLBCL: A rare case report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法是一项癌症治疗突破，可使既往治疗失败的血液系统恶性肿瘤患者获得持久缓解。随着CAR-T 疗法应用增加，治疗相关肾脏并发症值得特别关注，尤其是孤立肾患者，其肾脏并发症可能进一步增加临床风险。本文报告一名活体肾脏捐献者确诊弥漫大B细胞淋巴瘤（DLBCL）的病例。患者接受CAR-T 细胞治疗后仅发生轻度细胞因子释放综合征（CRS），未见急性肾损伤或肾功能受损，随后取得良好的代谢应答，接近完全缓解。
展开英文摘要原文
Chimeric antigen receptor T-cell (CAR-T) therapy is a breakthrough in cancer treatment that can induce durable remission in patients with hematological malignancies who have failed prior therapies. As the use of CAR-T cell therapy increases, treatment-related renal complications deserves careful attention, particularly in patients with a solitary kidney, in whom renal complications may further increase clinical risk.
Here, we report the case of a living kidney donor who was diagnosed with diffuse large B-cell lymphoma (DLBCL). After CAR-T cell therapy, the patient developed only mild cytokine release syndrome (CRS), without signs of acute kidney injury or renal impairment, and subsequently achieved a favorable metabolic response approaching complete remission.
论文信息
- 作者
- Zhang Q、Wu J、Meng F、Cao Y、Zhu X、Xiao Y
- 单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.China
- 文献类型
- 病例报告 · 非美国政府资助研究
- 期刊
- Cell transplantation2026 Jan-Dec
- 原文标识
- PubMed 42231134 · DOI 10.1177/09636897261446738